Oral presentation of Pr Martine Bagot (Hôpital Saint Louis, Paris)
IPH4102; An Anti-KIR3DL2 Monoclonal Antibody in Refractory Sezary Syndrome: Results from a Multicenter Phase 1 Trial
Monday, December 3, 2018, 11:45 AM
Room 6F (San Diego Convention Center)
Molecular Remissions with Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox are Associated with Improved Complete Remission Durations During Phase I and III Testing
Arons, E et al.
Saturday, December 1, 2018, 6:15-8-15PM
Hall GH (San Diego Convention Center)
Visit ASH website for more information.